In yesterday’s Wall Street session, Atossa Therapeutics Inc. (NASDAQ:ATOS) shares traded at $1.35, up 6.30% from the previous session.
2 analysts cover Atossa Therapeutics Inc. (NASDAQ:ATOS), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $5.25 and a low of $4.00, we find $4.63. Given the previous closing price of $1.27, this indicates a potential upside of 264.57 percent. ATOS stock price is now 50.78% away from the 50-day moving average and 71.25% away from the 200-day moving average. The market capitalization of the company currently stands at $170.94M.
The stock has received a hold rating from 0 analysts and a buy rating from 2. Brokers who have rated the stock have averaged $4.63 as their price target over the next twelve months.
With the price target of $2, Maxim Group recently initiated with Buy rating for Atossa Therapeutics Inc. (NASDAQ: ATOS).
A total of 0.04% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ATOS stock. A new stake in Atossa Therapeutics Inc. shares was purchased by BANK OF MONTREAL /CAN/ during the first quarter worth $237,000. LVM CAPITAL MANAGEMENT LTD/MI invested $28,000 in shares of ATOS during the first quarter. In the first quarter, NATIONAL BANK OF CANADA /FI/ acquired a new stake in Atossa Therapeutics Inc. valued at approximately $2,000. In total, there are 62 active investors with 21.50% ownership of the company’s stock.
On Wednesday morning Atossa Therapeutics Inc. (NASDAQ: ATOS) stock kicked off with the opening price of $1.3000. During the past 12 months, Atossa Therapeutics Inc. has had a low of $0.50 and a high of $1.39. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 37.70, and a quick ratio of 37.70. The fifty day moving average price for ATOS is $0.9096 and a two-hundred day moving average price translates $0.7911 for the stock.
The latest earnings results from Atossa Therapeutics Inc. (NASDAQ: ATOS) was released for Mar, 2023.
Atossa Therapeutics Inc.(ATOS) Company Profile
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company’s lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
